Skip to main content
NVDA-1.19%AAPL+0.67%GOOGL-2.28%MSFT-0.48%AMZN-0.82%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.20%TSLA-1.97%SKHY+7.05%MU-3.05%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.91%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%0005.HK-0.78%AP2d-2.69%UNH-1.94%DELL+0.29%HSBA.L-1.34%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.62%AUDJPY-1.87%CHFJPY-1.71%NZDCAD-1.45%GBPJPY-1.39%EURJPY-1.38%NZDUSD-1.37%EURNZD+1.28%USDJPY-1.28%GBPNZD+1.24%CADJPY-1.19%NZDCHF-0.95%USDZAR+0.95%USDSEK+0.88%USDNOK+0.87%AUDNZD+0.78%AUDCAD-0.72%EURZAR+0.67%USDTHB+0.61%USDMXN+0.61%AUDUSD-0.61%EURSEK+0.60%GBPZAR+0.59%EURNOK+0.59%AUDSGD-0.54%USDPLN+0.53%AUDDKK-0.52%CADCHF+0.51%EURAUD+0.50%CHFSEK+0.49%CHFNOK+0.48%GBPAUD+0.47%USDCHF+0.45%GBPTRY+0.41%NOKJPY-0.41%NZDSGD-0.38%GBPHKD+0.32%EURCHF+0.32%GBPCHF+0.30%EURHKD-0.30%GBPMXN-0.28%USDDKK+0.28%USDSGD+0.27%EURPLN+0.25%GBPCAD-0.22%EURCAD-0.20%SGDJPY+0.19%EURCNH-0.17%AUDCHF-0.17%USDILS+0.16%CHFSGD-0.12%GBPUSD-0.12%EURUSD-0.12%USDTRY+0.11%USDCNH+0.09%GBPSGD-0.09%USDCAD-0.08%PLNJPY-0.07%NZDMXN-0.06%AUDNOK+0.06%USDCOP-0.04%EURCZK-0.03%EURGBP+0.03%EURSGD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.86%XAGUSD-4.32%GAGUSD-4.32%HG1-4.09%UKOIL+3.27%USOIL+3.15%COFFEE-2.45%GAUUSD-1.17%XAUUSD-1.17%SUGAR+1.15%COTTON+0.60%XNGUSD-0.29%BTCUSD-1.81%ETHUSD-2.01%USDTUSD-0.02%XRPUSD-2.77%SOLUSD-2.07%TRXUSDT-0.17%ZECUSDT-5.51%DOGEUSD-2.88%XMRUSDT-2.04%LINKUSD-1.08%XLMUSD-2.10%BCHUSDT-8.60%LTCUSD-2.09%UNIUSD-4.73%TONUSD+24.88%HBARUSDT-2.37%SUIUSD-2.75%TAOUSDT-4.55%AAVEUSD-3.25%DOTUSDT-2.63%ICPUSDT-1.30%ONDOUSDT-2.87%WLDUSDT-2.43%ATOMUSDT-3.41%ARBUSDT-1.04%JUPUSDT-3.82%INJUSDT-3.30%STXUSDT-3.80%FETUSDT-3.24%TIAUSDT-1.65%SEIUSDT-3.91%PYTHUSDT-1.17%IMXUSDT-3.06%WIFUSDT-4.40%GRTUSDT-3.82%OPUSDT-3.00%IOTAUSDT-3.80%POLUSDT-7.08%AXSUSDT-2.57%FARTCOINUSDT-3.67%EOSUSDT-1.86%DYDXUSDT-0.24%ORDIUSDT-0.69%GALAUSDT-4.78%NOTUSDT-0.68%RONINUSDT-2.64%NVDA-1.19%AAPL+0.67%GOOGL-2.28%MSFT-0.48%AMZN-0.82%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.20%TSLA-1.97%SKHY+7.05%MU-3.05%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.91%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%0005.HK-0.78%AP2d-2.69%UNH-1.94%DELL+0.29%HSBA.L-1.34%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.62%AUDJPY-1.87%CHFJPY-1.71%NZDCAD-1.45%GBPJPY-1.39%EURJPY-1.38%NZDUSD-1.37%EURNZD+1.28%USDJPY-1.28%GBPNZD+1.24%CADJPY-1.19%NZDCHF-0.95%USDZAR+0.95%USDSEK+0.88%USDNOK+0.87%AUDNZD+0.78%AUDCAD-0.72%EURZAR+0.67%USDTHB+0.61%USDMXN+0.61%AUDUSD-0.61%EURSEK+0.60%GBPZAR+0.59%EURNOK+0.59%AUDSGD-0.54%USDPLN+0.53%AUDDKK-0.52%CADCHF+0.51%EURAUD+0.50%CHFSEK+0.49%CHFNOK+0.48%GBPAUD+0.47%USDCHF+0.45%GBPTRY+0.41%NOKJPY-0.41%NZDSGD-0.38%GBPHKD+0.32%EURCHF+0.32%GBPCHF+0.30%EURHKD-0.30%GBPMXN-0.28%USDDKK+0.28%USDSGD+0.27%EURPLN+0.25%GBPCAD-0.22%EURCAD-0.20%SGDJPY+0.19%EURCNH-0.17%AUDCHF-0.17%USDILS+0.16%CHFSGD-0.12%GBPUSD-0.12%EURUSD-0.12%USDTRY+0.11%USDCNH+0.09%GBPSGD-0.09%USDCAD-0.08%PLNJPY-0.07%NZDMXN-0.06%AUDNOK+0.06%USDCOP-0.04%EURCZK-0.03%EURGBP+0.03%EURSGD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.86%XAGUSD-4.32%GAGUSD-4.32%HG1-4.09%UKOIL+3.27%USOIL+3.15%COFFEE-2.45%GAUUSD-1.17%XAUUSD-1.17%SUGAR+1.15%COTTON+0.60%XNGUSD-0.29%BTCUSD-1.81%ETHUSD-2.01%USDTUSD-0.02%XRPUSD-2.77%SOLUSD-2.07%TRXUSDT-0.17%ZECUSDT-5.51%DOGEUSD-2.88%XMRUSDT-2.04%LINKUSD-1.08%XLMUSD-2.10%BCHUSDT-8.60%LTCUSD-2.09%UNIUSD-4.73%TONUSD+24.88%HBARUSDT-2.37%SUIUSD-2.75%TAOUSDT-4.55%AAVEUSD-3.25%DOTUSDT-2.63%ICPUSDT-1.30%ONDOUSDT-2.87%WLDUSDT-2.43%ATOMUSDT-3.41%ARBUSDT-1.04%JUPUSDT-3.82%INJUSDT-3.30%STXUSDT-3.80%FETUSDT-3.24%TIAUSDT-1.65%SEIUSDT-3.91%PYTHUSDT-1.17%IMXUSDT-3.06%WIFUSDT-4.40%GRTUSDT-3.82%OPUSDT-3.00%IOTAUSDT-3.80%POLUSDT-7.08%AXSUSDT-2.57%FARTCOINUSDT-3.67%EOSUSDT-1.86%DYDXUSDT-0.24%ORDIUSDT-0.69%GALAUSDT-4.78%NOTUSDT-0.68%RONINUSDT-2.64%
IB

Inhibrx Biosciences Inc. (INBX)

NASDAQ • Healthcare

$112.86
-$1.48 (-1.3%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$117.38
Previous Close$112.86
Day Range$112.03 - $128.54
Avg. Volume (3M)370K
Market Cap$1.6B
52 Week Range
$26.19$155.29
Next EarningsIn 64 daysNov 13, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$138.1M
EPS (TTM)
-$8.88
ROA (TTM)
-89.6%
Current Ratio
5.07
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-1.4%Q1 2026-$2.11
+9.3%Q2 2026-$2.15
-2.6%Q3 2026-$2.34
Next

Nov 13

in 64 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -2.6%

Inhibrx Biosciences’ preliminary results for the second fiscal quarter of 2026 showed a wider loss than consensus expected, with EPS of -$2.34 trailing the -$2.28 estimate by -$0.06 when it reported on August 13, 2026. Net income was a loss of roughly $36.6 million, down 27.9% from a loss of about $28.7 million a year ago, alongside an operating loss of around $32.1 million as the company continued funding development work across its pipeline programs, including INBRX-109 and INBRX-106. On a per-share basis, EPS was down 26.5% year over year from -$1.85. Cash usage also remained elevated, with negative operating cash flow of about $29.9 million in the quarter. For the next period, consensus calls for EPS of -$2.39 on revenue of $1.9 million.

View full earnings history

About Inhibrx Biosciences Inc.

Inhibrx Biosciences Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops therapeutic candidates with proprietary modular protein engineering platforms. Founded in 2024 and based in La Jolla, California, Inhibrx is an early-stage drug developer built around a focused pipeline rather than a marketed product base.

Name
Inhibrx Biosciences Inc.
CEO
Mark Lappe
Website
www.inhibrx.com
Industry
Healthcare
Year Founded
2024
Employees
110

Today's Snapshot

AI-generated

Yesterday INBX fell 1.3% to 112.86.

Trading Volume

Above 10d avg 441.3K

658K

vs S&P 500 Today

Underperforming Market

-0.81%

Updated: September 10, 2026 at 12:28 UTC

Technical Indicators

4 Buy3 Neutral1 Sell
INBX shows a constructive medium-to-long-term setup despite short-term weakness. The stock sits above its 50/100/200-day moving averages while trading slightly below the 10-day average, and the MACD and RSI are neutral-to-holding, indicating restrained momentum. ADX near the mid-20s suggests a moderate trend rather than a strong directional drive, while ATR at around 8% signals elevated intraday range and OBV pressure is negative, tempering the picture. The classic pivot near 109.5 is just below the current price, providing a nearby reference. Technical takeaway: Buy — longer-term averages support the bullish bias despite short-term softness.
All signals
  • EMA (5 indicators)$85.56 - $117.37
    Buy
  • RSI (14)54.83
    Neutral
  • Stochastic %K (14, 3, 3)60.83
    Neutral
  • MACD Level (12, 26)7.19
    Neutral

Peers & Related Assets

ELVNEnliven Therapeutics, Inc.
$57.45-3.2%
RLAYRelay Therapeutics, Inc.
$18.66-2.4%
AMLXAmylyx Pharmaceuticals, Inc.
$32.4-4.4%
SNDXSyndax Pharmaceuticals, Inc.
$19.84-0.5%
ORICORIC Pharmaceuticals, Inc.
$12.5-0.9%
SANASana Biotechnology, Inc.
$3.17-8.1%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.